Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Albendazole treatment of HIV-1 and helminth co-infection: A randomized, double-blind, placebo-controlled trial
AIDS, Volume 22, No. 13, Year 2008
Notification
URL copied to clipboard!
Description
Objective:: Several co-infections have been shown to impact the progression of HIV-1 infection. We sought to determine if treatment of helminth co-infection in HIV-1-infected adults impacted markers of HIV-1 disease progression. Design:: To date, there have been no randomized trials to examine the effects of soil-transmitted helminth eradication on markers of HIV-1 progression. Methods:: A randomized, double-blind, placebo-controlled trial of albendazole (400 mg daily for 3 days) in antiretroviral-naive HIV-1-infected adults (CD4 cell count >200 cells/μl) with soil-transmitted helminth infection was conducted at 10 sites in Kenya (Clinical Trials.gov NCT00130910). CD4 and plasma HIV-1 RNA levels at 12 weeks following randomization were compared in the trial arms using linear regression, adjusting for baseline values. Results:: Of 1551 HIV-1-infected individuals screened for helminth infection, 299 were helminth infected. Two hundred and thirty-four adults were enrolled and underwent randomization and 208 individuals were included in intent-to-treat analyses. Mean CD4 cell count was 557 cells/μl and mean plasma viral load was 4.75 log10 copies/ml at enrollment. Albendazole therapy resulted in significantly higher CD4 cell counts among individuals with Ascaris lumbricoides infection after 12 weeks of follow-up (+109 cells/μl; 95% confidence interval +38.9 to +179.0, P ≤ 0.003) and a trend for 0.54 log10 lower HIV-1 RNA levels (P ≤ 0.09). These effects were not seen with treatment of other species of soil-transmitted helminths. Conclusion:: Treatment of A. lumbricoides with albendazole in HIV-1-coinfected adults resulted in significantly increased CD4 cell counts during 3-month follow-up. Given the high prevalence of A. lumbricoides infection worldwide, deworming may be an important potential strategy to delay HIV-1 progression. © 2008 Wolters Kluwer Health | Lippincott Williams & Wilkins.
Authors & Co-Authors
Walson, Judd L.
United States, Halifax
Centre for Clinical Research
United States, Seattle
Fred Hutchinson Cancer Research Center
Otieno, Phelgona Apondi O.
United States, Halifax
Centre for Clinical Research
Mbuchi, Margaret W.
United States, Halifax
Centre for Clinical Research
Richardson, Barbra Ann
United States, Seattle
Fred Hutchinson Cancer Research Center
Lohman-Payne, Barbara L.
Kenya, Nairobi
University of Nairobi
United States, Seattle
Fred Hutchinson Cancer Research Center
MacHaria, Steven W.
United States, Halifax
Centre for Clinical Research
Overbaugh, Julie M.
United States, Seattle
Fred Hutchinson Cancer Research Center
Berkley, James A.
Kenya, Kilifi
Centre for Geographic Medicine Research
United Kingdom, Oxford
University of Oxford
Sanders, Eduard Joachim
Kenya, Kilifi
Centre for Geographic Medicine Research
United Kingdom, Oxford
University of Oxford
Chung, Michael Hoonbae
United States, Seattle
Fred Hutchinson Cancer Research Center
John-Stewart, Grace C.
United States, Seattle
Fred Hutchinson Cancer Research Center
United States, Seattle
University of Washington
Statistics
Citations: 110
Authors: 11
Affiliations: 6
Identifiers
Doi:
10.1097/QAD.0b013e32830a502e
e-ISSN:
14735571
Research Areas
Disability
Infectious Diseases
Study Design
Randomised Control Trial
Cross Sectional Study
Cohort Study
Study Locations
Kenya